Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

March 31, 2017

Study Completion Date

March 31, 2017

Conditions
Ovarian Cancer
Interventions
DRUG

pazopanib in combination with weekly topotecan

"* Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and~* Pazopanib orally once daily continuous dosing in the following dose levels:~Phase I Trial:~Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg~Phase II Trial:~Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."

Trial Locations (1)

13353

RECRUITING

Charité Campus Virchow-Klinikum, Berlin

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

JSehouli

OTHER